论文部分内容阅读
目的:探讨补肺化瘀通络汤对慢性肺栓塞患者凝血功能的影响。方法:选取2013年2月至2015年6月我院收治的慢性肺栓塞患者86例为研究对象,采用随机数表法分为观察组和对照组各43例,对照组取常规西药治疗,观察组在此基础上加用补肺化瘀通络汤,均治疗2个月,比较两组治疗有效率,应用酶联免疫吸附试验(ELISA)分析治疗前后两组血清高迁移率族蛋白B1(HMGB-1)水平,并比较1s用力呼气容积(FVE1)占预计值%、FVE1与用力肺活量(FVC)比值(FVE1/FVC),监测凝血酶原时间(PT)、纤维蛋白原(FIB)、血小板计数(PLT)变化情况,同时观察不良反应发生率。结果:观察组治疗有效率95.3%高于对照组81.4%(P<0.05);治疗后观察组FVE1占预计值(71.25±1.48)%、FVE1/FVC(76.32±1.29)%、PT(11.40±1.27)s、FIB(2.60±0.48)g/L、PLT(2.49±0.17)×1011/L高于对照组(P<0.05),观察组HMGB-1(2.15±0.43)μg/L较对照组低(P<0.05);两组不良反应发生率7.0%、2.3%比较无显著差异(P>0.05)。结论:补肺化瘀通络汤可有效改善慢性肺栓塞患者肺功能、凝血功能,不会增加不良反应,值得在临床推广应用。
Objective: To investigate the effect of Bufei Huayu Tongluo Decoction on coagulation function in patients with chronic pulmonary embolism. Methods: From February 2013 to June 2015 in our hospital, 86 cases of chronic pulmonary embolism patients were selected as the research object, using random number table method was divided into observation group and control group, 43 cases each, the control group taking conventional western medicine, observed On this basis, the group was treated with Bufei Huayu Tongluo Decoction for 2 months, and the treatment efficiency was compared between the two groups. ELISA and ELISA were used to analyze the serum high mobility group box B1 (FVE1 / FVC), Fibrinogen (FIB), fibrinogen (FIB), fibrinogen (FIB), fibrinogen , Platelet count (PLT) changes, while observing the incidence of adverse reactions. Results: The effective rate of observation group was 95.3% higher than that of control group (81.4%, P <0.05). After treatment, FVE1 accounted for 71.25 ± 1.48%, FVE1 / FVC was 76.32 ± 1.29% 1.27) s, FIB (2.60 ± 0.48) g / L and PLT (2.49 ± 0.17) × 1011 / L were higher than those of the control group (P <0.05) (P <0.05). There was no significant difference between the two groups (7.0% vs 2.3%) (P> 0.05). Conclusion: Bufei Huayu Tongluo Decoction can effectively improve pulmonary function and coagulation function in patients with chronic pulmonary embolism without increasing adverse reactions, which is worthy of clinical application.